Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and efficacy of Mirabegron compared to Solifenacin for the treatment of Overactive bladder symptoms in patients with Multiple Sclerosis

Trial Profile

Safety and efficacy of Mirabegron compared to Solifenacin for the treatment of Overactive bladder symptoms in patients with Multiple Sclerosis

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 26 Sep 2018

At a glance

  • Drugs Mirabegron (Primary) ; Solifenacin (Primary)
  • Indications Overactive bladder
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 26 Sep 2018 New trial record
    • 31 Aug 2018 Initial results (n=45) presented at the 48th Annual Meeting of the International Continence Society
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top